Pharma & Biotech

Cencora, one of the largest pharmaceutical distribution companies in the United States, is deploying artificial intelligence to sharpen how it anticipates and responds to drug demand across its network. Demand sensing represents

Cold chain logistics remains one of the most technically demanding disciplines in pharmaceutical supply chain management, requiring precise packaging decisions at every stage. GEODIS’ David Frouin has emerged as a key voice

At LogiPharma USA 2026, supply chain leaders gathered to examine where artificial intelligence delivers genuine value across pharmaceutical distribution networks. PAXAFE’s Mark Talens took to the stage to deliver a clear message:

Octapharma USA’s Kerem Tokel has outlined how evolving regulatory and trade pressures are reshaping the risks facing pharmaceutical supply chains across the United States. Tokel, speaking in the context of LogiPharma USA

LogiPharma USA 2026 is shaping up to be one of the most substantive gatherings in pharmaceutical supply chain and logistics this year. The event is drawing senior industry figures eager to address

Patient support programmes generate vast amounts of data, but the real question is whether that data can drive meaningful action and genuine improvement. Many organisations collect and report on patient support metrics

LogiPharma’s 2026 agenda is taking shape around three core themes: supply chain resilience, practical artificial intelligence applications, and fresh peer engagement formats. The pharmaceutical supply chain sector has faced mounting pressure in

Health system pharmacies are under pressure to demonstrate they can manage rebate reconciliation at scale before a major federal pilot programme begins. The Health Resources and Services Administration has closed its approval

Waltz Health and Fresenius Kabi are moving to offer three biosimilars through a direct-to-payer model, bypassing traditional wholesaler and pharmacy benefit manager rebate channels entirely. The partnership represents a significant shift in

Novo Nordisk’s chief executive has signalled openness to listing the Danish drugmaker’s shares directly on the New York Stock Exchange. CEO Doustdar told a newspaper that he sees clear advantages in pursuing